An Open-label, Randomized Crossover Study to Evaluate the Effect of ipragliflozin on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa

Trial Profile

An Open-label, Randomized Crossover Study to Evaluate the Effect of ipragliflozin on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Ipragliflozin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Oct 2012 Part 1 results published in the Diabetes, Obesity and Metabolism.
    • 18 Apr 2012 Results published in the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 02 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top